What is the long-term efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity in primary care?
University of Utah, Salt Lake City, USA. Jennifer.leiser@hsc.utah.edu
J P
JP
Leiser
K
K
Gunning
D019440:Anti-Obesity Agents / Q000191:economics / Q000627:therapeutic use*; D001835:Body Weight; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use*; D005194:Family Practice; D005260:Female; D006801:Humans; D007783:Lactones / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D015337:Multicenter Studies as Topic; D009765:Obesity / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D000077403:Orlistat; D011306:Prescription Fees; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results
D019440:Anti-Obesity Agents; D004791:Enzyme Inhibitors; D007783:Lactones; D000077403:Orlistat